

Table S2: Statistical analysis of clinical parameters for all patients treated with Casirivimab/Imdevimab. Missing data were excluded, causing different numbers for each parameter. Data for all cases can be found in Table S1. Average \pm standard deviation is shown. For metric parameters significance was determined using Student's T-test, Cross tables were analysed using Fisher's exact test. $p < 0.1$: +; $p < 0.05$: *; $p < 0.01$: **. Significance signs in "All" in the female table indicate significant difference to the male sex.

Parameter	All patients		
	All	untreated	treated
Number	693	94	602
Age	64.3 \pm 17.0	65.6 \pm 21.2	64.1 \pm 16.2
Sex (f/m)	385/308	59/37	326/271
Female %	55.6 %	61.5 %	54.6 %
Symptoms			
Coughing (n/y)	276/382	54/36	222/346 **
% yes	58.1 %	40.0 %	60.9 %
Dyspnea (n/y)	498/158	47/43	451/115 **
% yes	24.1 %	47.8 %	20.3 %
Fatigue (n/y)	488/166	69/21	419/145
% yes	25.4 %	23.3 %	25.4 %
Pain (n/y)	417/238	70/20	347/218 **
% yes	36.3 %	22.2 %	38.6 %
Inappetence (n/y)	569/87	76/14	493/73
% yes	13.3 %	15.5 %	12.9 %
Loss of taste and smell (n/y)	598/57	86/4	512/53
% yes	8.7 %	4.4 %	9.4 %
Diarrhoea / vomiting (n/y)	575/81	81/9	494/72
% yes	12.3 %	10.0 %	12.7 %
Fever (n/y)	447/209	54/36	393/173 +
% yes	31.9 %	40 %	30.6 %
Temperature	37.3 \pm 1.0	37.3 \pm 1.0	37.3 \pm 1.0
Neurological Symptoms (n/y) % yes	620/36	84/6	536/30
% yes	5.5 %	6.7 %	5.3 %
Syncope (n/y)	629/27	80/10	549/17 **
% yes	4.1 %	11.1 %	3.0 %
Preexisting illness			
Hypertension (n/y)	299/357	44/49	255/308
% yes	54.4 %	52.7 %	54.7 %
Blood pressure systolic	127.9 \pm 19.0	125.0 \pm 22.2	128.3 \pm 18.6
Blood pressure diastolic	77.9 \pm 12.3	73.6 \pm 11.7	78.4 \pm 12.3 **
Cardiac frequency (1/min)	82.1 \pm 16.1	84.3 \pm 15.7	81.4 \pm 16.9
Diabetes (n/y)	519/138	69/24	450/114
% yes	21.0 %	25.8 %	20.2 %
Renal insufficiency (n/y)	553/102	73/20	480/82 +
% yes	15.6 %	21.5 %	14.6 %
COPD/Asthma (n/y)	538/118	72/21	466/97
% yes	18.0 %	22.6 %	17.2 %
Active malignoma (n/y)	600/57	86/7	514/50
% yes	8.7 %	7.5 %	8.9 %
Inactive malignoma (n/y)	624/31	86/6	538/25
% yes	4.7 %	6.5 %	4.4 %

Immunosuppression (n/y)	621/35	90/3	531/32
% yes	5.3 %	3.2 %	5.7 %
Obesity (n/y)	537/117	73/19	464/98
% yes	17.9 %	20.7 %	17.4 %
Heart disease (n/y)	494/160	62/31	432/129 *
% yes	24.5 %	33.3 %	23.0 %
Hypothyreosis (n/y)	579/75	76/16	503/59 +
% yes	11.5 %	17.4 %	10.5 %
Blood gas analysis			
pO ₂	10.2 ± 2.8	9.7 ± 4.4	10.3 ± 2.3
pCO ₂	4.8 ± 0.7	4.7 ± 0.9	4.8 ± 0.7
O ₂ -Saturation %	94.0 ± 5.4	92.5 ± 4.9	94.3 ± 5.4 **
Clinical chemistry			
Hemoglobin (mM)	8.4 ± 1.3	8.2 ± 1.2	8.5 ± 1.3 +
Leukocytes (Gpt/L)	6.3 ± 4.6	7.5 ± 4.3	6.1 ± 4.6 **
Lymphocytes (Gpt/L)	1.5 ± 2.2	1.5 ± 2.2	1.6 ± 2.2
Thrombocytes (Gpt/L)	205.7 ± 77.8	204.9 ± 88.6	205.8 ± 75.8
CRP (mg/L)	39.7 ± 53.5	69.2 ± 69.3	34.3 ± 48.2 **
proBNP (mg/mL)	2297 ± 4598	2413 ± 5191	2230 ± 4243
Troponin (ng/mL)	0.05 ± 0.17	0.08 ± 0.30	0.04 ± 0.09
Blood glucose (mM)	8.2 ± 9.9	9.6 ± 16.5	7.7 ± 5.7
Creatinin(μM)	105.6 ± 109.3	111.3 ± 111.4	105.7 ± 109.0
GFR (mL/min/1.73m ²)	74.9 ± 28.1	72.4 ± 34.0	75.3 ± 27.0
PCR (Ct)	24.7 ± 5.3	26.7 ± 4.9	24.2 ± 5.3 **
Hospitalization (d)	5.7 ± 9.0	14.4 ± 11.1	4.0 ± 7.4 **
Death (n/y)	579/39	77/17	502/22 **
% yes	6.3 %	18.1 %	4.2 %

Parameter	Female		
	All	untreated	treated
Number	385	59	326
Age	66.0 ± 17.2	64.7 ± 21.0	66.2 ± 16.4
Symptoms			
Coughing (n/y)	145/205	31/22	114/138 **
% yes	58.6 %	41.5 %	61.6 %
Dyspnea (n/y)	262/88	25/28	237/60 **
% yes	25.1 %	52.8 %	20.2 %
Fatigue (n/y)	90/349	37/16	222/74
	25.8 %	30.2 %	25.0 %
Pain (n/y)	219/130	38/15	181/115
% yes	37.2 %	38.9 %	28.3 %
Inappetence (n/y)	297/53	44/9	253/44
% yes	15.1 %	17.0 %	14.8 %
Loss of taste and smell (n/y)	317/32	52/1	265/31 +
% yes	9.2 %	1.9 %	10.5 %
Diarrhoea / vomitting (n/y)	296/54 *	46/7	250/47
% yes	15.4 %	13.2 %	15.8 %
Fever (n/y)	240/110	31/22	209/88
% yes	31.4 %	41.5 %	29.6 %
Temperature	37.3 ± 1.0	37.2 ± 1.0	37.4 ± 1.0
Neurological Symptoms	326/24	49/4	277/20

(n/y) % yes	6.9%	7.5 %	6.7%
Syncope (n/y)	336/14	46/7	290/7 **
% yes	4.0 %	13.2 %	2.4 %
Preexisting illness			
Hypertension (n/y)	163/185	27/28	136/157
% yes	53.2 %	50.9 %	53.6 %
Blood pressure systolic	127.0 ± 20.5	123.9 ± 24.4	127.4 ± 20.0
Blood pressure diastolic	76.6 ± 12.2	72.8 ± 12.4	77.1 ± 12.2 *
Cardiac frequency (1/min)	82.1 ± 16.1	83.7 ± 14.5	81.6 ± 16.7
Diabetes (n/y)	286/62 *	44/11	242/51
% yes	17.8 %	20.0 %	17.4 %
Renal insufficiency (n/y)	291/57	45/10	246/47
% yes	16.4 %	18.2 %	16.0 %
COPD/Asthma (n/y)	284/64	44/11	240/53
% yes	18.4 %	20.0 %	18.1 %
Active malignoma (n/y)	325/23 +	53/2	272/21
% yes	6.6 %	3.6 %	7.2 %
Inactive malignoma (n/y)	332/15	50/5	282/10 +
% yes	4.3 %	9.1 %	3.4 %
Immunosuppression (n/y)	327/21	54/1	273/20
% yes	6.0 %	1.8 %	6.8 %
Obesity (n/y)	280/68	40/15	240/53
% yes	19.5 %	27.3 %	18.1 %
Heart disease (n/y)	271/75 +	38/16	232/59
% yes	21.7 %	29.1 %	20.3 %
Hypothyreosis (n/y)	250/57 **	42/13	248/44
% yes	16.4 %	23.6 %	15.1 %
Blood gas analysis			
pO ₂	10.2 ± 2.3	9.1 ± 2.2	10.4 ± 2.3 **
pCO ₂	4.8 ± 0.7	4.8 ± 1.0	4.8 ± 0.7
O ₂ -Saturation (%)	94.1 ± 5.9	92.3 ± 3.9	94.5 ± 6.1 *
Clinical chemistry			
Hemoglobin (mM)	8.2 ± 1.1 **	8.0 ± 1.1	8.2 ± 1.1
Leukocytes (Gpt/L)	5.9 ± 3.0 *	7.1 ± 3.6	5.7 ± 2.9 **
Lymphocytes (Gpt/L)	1.3 ± 1.0 *	1.4 ± 1.3	1.2 ± 1.0
Thrombocytes (Gpt/L)	211.5 ± 75.4 *	213.2 ± 88.6	211.2 ± 72.5
CRP (mg/L)	35.8 ± 48.0 +	56.9 ± 57.8	31.2 ± 44.3 **
proBNP (mg/mL)	2255 ± 4232	2057 ± 4386	2370 ± 4172
Troponin (ng/mL)	0.04 ± 0.10	0.04 ± 0.09	0.03 ± 0.10
Blood glucose (mM)	8.3 ± 12.0	10.2 ± 21.1	7.5 ± 4.1
Creatinin(μM)	89.3 ± 73.6 **	90.5 ± 63.3	89.1 ± 75.7
GFR (mL/min/1.73m ²)	75.5 ± 28.4	74.8 ± 34.9	75.7 ± 26.8
PCR (Ct)	24.9 ± 5.3	27.0 ± 5.1	24.3 ± 5.2 **
Hospitalization (d)	6.4 ± 9.8 +	16.2 ± 11.9	4.2 ± 7.8 **
Death (n/y)	304/19	51/6	253/13
% yes	5.9 %	10.5 %	4.9 %
Parameter			
	All	untreated	treated
Number	308	37	271
Age	62.3 ± 14.5	66.9 ± 21.7	61.7 ± 15.6
Symptoms			

Coughing (n/y)	131/177	23/14	108/163 *
% yes	57.5 %	37.8 %	60.1 %
Dyspnea (n/y)	236/70	22/15	214/55 *
% yes	22.9 %	40.5 %	20.4 %
Fatigue (n/y)	229/76	32/5	197/71
	24.9 %	13.5 %	26.5 %
Pain (n/y)	198/108	32/5	166/103 **
% yes	35.3 %	13.5 %	38.3 %
Inappetence (n/y)	272/34	32/5	240/29
% yes	11.1 %	13.5 %	10.8 %
Loss of taste and smell (n/y)	281/25	34/3	247/22
% yes	8.2 %	8.1 %	8.2 %
Diarrhoea / vomiting (n/y)	279/27	35/2	244/25
% yes	8.8 %	5.4 %	9.3 %
Fever (n/y)	207/99	23/14	184/85
% yes	32.4 %	37.8 %	31.6 %
Temperature	37.3 ± 1.0	37.4 ± 1.0	37.3 ± 1.0
Neurological Symptoms (n/y) % yes	294/12 3.9 %	35/2 5.4 %	295/10 3.7 %
Syncope (n/y)	293/13	34/3	259/10
% yes	4.2 %	8.1 %	3.7 %
Preexisting illness			
Hypertension (n/y)	136/172	17/21	119/151
% yes	55.8 %	55.3 %	55.9
Blood pressure systolic	129.1 ± 17.0	127.0 ± 18.1	129.3 ± 17.0
Blood pressure diastolic	79.4 ± 12.2	75.1 ± 10.3	79.8 ± 12.3
Cardiac frequency (1/min)	82.0 ± 17.3	85.3 ± 17.9	81.2 ± 17.2
Diabetes (n/y)	233/76	25/13	208/63
% yes	24.6 %	34.2 %	23.2 %
Renal insufficiency (n/y)	262/45	28/10	234/35 *
% yes	14.7 %	26.3 %	13.0 %
COPD/Asthma (n/y)	254/54	28/10	226/44
% yes	17.5 %	26.3 %	16.3 %
Active malignoma (n/y)	275/34	33/5	242/29
% yes	11.0 %	13.2 %	10.7 %
Inactive malignoma (n/y)	292/16	36/1	256/15
% yes	5.2 %	2.7 %	5.5 %
Immunosuppression (n/y)	294/14	36/2	258/12
% yes	4.5 %	5.3 %	4.4 %
Obesity (n/y)	257/49	33/4	224/45
% yes	16.0 %	10.8 %	16.7 %
Heart disease (n/y)	223/85	23/15	200/70
% yes	27.6 %	39.5 %	25.9 %
Hypothyreosis (n/y)	289/18	34/3	255/15
% yes	5.9 %	8.1 %	5.6 %
Blood gas analysis			
pO ₂	10.2 ± 3.2	10.5 ± 6.4	10.1 ± 2.4
pCO ₂	4.8 ± 0.7	4.7 ± 0.8	4.8 ± 0.6
O ₂ -Saturation (%)	93.9 ± 4.7	92.8 ± 6.2	94.1 ± 4.5
Clinical chemistry			
Hemoglobin (mM)	8.7 ± 1.4	8.5 ± 1.4	8.7 ± 1.4

Leukocytes (Gpt/L)	6.7 ± 5.8	8.0 ± 5.2	6.5 ± 5.8
Lymphocytes (Gpt/L)	1.9 ± 2.9	1.8 ± 3.2	1.9 ± 2.9
Thrombocytes (Gpt/L)	199 ± 80	191.7 ± 88.3	200.0 ± 78.9
CRP (mg/L)	44.2 ± 59.0	88.7 ± 81.4	37.6 ± 52.0 **
proBNP (mg/mL)	2355 ± 5091	2911 ± 6209	2038 ± 4380
Troponin (ng/mL)	0.06 ± 0.23	0.14 ± 0.47	0.04 ± 0.08
Blood glucose (mM)	8.1 ± 6.5	8.8 ± 4.2	7.9 ± 7.1
Creatinin(μM)	126.4 ± 136.9	142.2 ± 154.1	124.0 ± 134.3
GFR (mL/min/1.73m ²)	74.1 ± 27.9	68.8 ± 32.8	74.9 ± 27.1
Hospitalization (d)	4.9 ± 7.9	11.9 ± 9.5	3.8 ± 7.0 **
PCR (Ct)	24.5 ± 5.3	26.2 ± 4.6	24.1 ± 5.4 *
Death (n/y)	275/20	26/11	249/9 **
% yes	6.8 %	29.7 %	3.5 %